

Cara Therapeutics, Inc.  
Form 8-K  
June 08, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 6, 2018**

**CARA THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**4 Stamford Plaza**

**001-36279**  
**(Commission**

**File Number)**

**75-3175693**  
**(IRS Employer**

**Identification No.)**

**06902**

**107 Elm Street, 9<sup>th</sup> Floor**

**Stamford, Connecticut**

**(Address of principal executive  
offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (203) 406-3700**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2.):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 6, 2018, Cara Therapeutics, Inc. (the Company) held its Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the Company's stockholders voted on the two proposals set forth below. A more detailed description of each proposal is set forth in the Company's Proxy Statement filed with the Securities and Exchange Commission on April 26, 2018.

**Proposal 1 Election of Directors**

Mr. Harrison M. Bains, Jr. was elected to serve as a director of the Company's Board of Directors until the 2021 Annual Meeting of Stockholders and until his successor is duly elected or until his earlier resignation or removal, by the following votes:

Nominee	Votes For	Votes Withheld	Broker Non-Votes
Harrison M. Bains, Jr.	5,782,274	1,693,373	15,901,958

**Proposal 2 Ratification of the Selection of Independent Registered Public Accounting Firm**

The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2018, by the following votes:

Votes For	Votes Against	Votes Abstain
23,083,086	196,120	98,399

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CARA THERAPEUTICS, INC.**

By: /s/ Mani Mohindru  
Mani Mohindru, Ph.D.  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

Date: June 8, 2018